IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Sarepta settles patent litigation with REGENXBIO, UPenn, Catalent over gene therapy capsidSep 23Partnershipdelandistrogene moxeparvovecSarepta Therapeutics, Inc.
REGENXBIO, UPenn settle patent suit with Sarepta over ELEVIDYSSep 23Partnershipdelandistrogene moxeparvovecREGENXBIO Inc.
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updatesAug 5Quarterly updateSarepta Therapeutics, Inc.